articleTop 1% cited

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research · 2008 · Vol. 14(19) · pp. 6302–6309

Johann S. de Bono✉(Royal Marsden Hospital)Howard I. Scher(Memorial Sloan Kettering Cancer Center)Bruce Montgomery(University of Washington)Christopher Parker(Royal Marsden Hospital)Michael Craig Miller(Eon Corporation (United States))H. Tissing(Eon Corporation (United States))Gerald V. Doyle(Eon Corporation (United States))Leon W.M.M. Terstappen(Eon Corporation (United States))Kenneth J. Pienta(University of Michigan–Ann Arbor)Derek Raghavan(Cleveland Clinic)

View via DOI Publisher page

Abstract

CTC are the most accurate and independent predictor of OS in CRPC. These data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.

Cancer Cells and Metastasis Prostate Cancer Treatment and Research Cancer Genomics and DiagnosticsMedicineProstate cancerCirculating tumor cellHazard ratioUrologyProportional hazards modelInternal medicineOncologyProspective cohort studyChemotherapy

MeSH terms

AgedAged, 80 and overAlgorithmsCastrationHumansMaleMiddle AgedNeoplastic Cells, CirculatingNeoplasm MetastasisPrognosisProstatic NeoplasmsTime FactorsProportional Hazards ModelsTreatment OutcomeDisease Progression

Citations

2,175

FWCI

36.32

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition